Machine perfusion of thoracic organs.

This article summarizes recent knowledge and clinical advances in machine perfusion (MP) of thoracic organs. MP of thoracic organs has gained much attention during the last decade. Clinical studies are investigating the role of MP to preserve, resuscitate, and assess heart and lungs prior to transplantation. Currently, MP of the cardiac allograft is essential in all type DCD heart transplantation while MP of the pulmonary allograft is mandatory in uncontrolled DCD lung transplantation. MP of thoracic organs also offers an exciting platform to further investigate downregulation of the innate and adaptive immunity prior to reperfusion of the allograft in recipients. MP provides a promising technology that allows pre-transplant preservation, resuscitation, assessment, repair, and conditioning of cardiac and pulmonary allografts outside the body in a near physiologic state prior to planned transplantation. Results of ongoing clinical trials are awaited to estimate the true clinical value of this new technology in advancing the field of heart and lung transplantation by increasing the total number and the quality of available organs and by further improving recipient early and long-term outcome.
Competing Interests: Conflicts of Interest: D Van Raemdonck was a principal investigator for the Inspire Trial and for the Expand Trial; both trials were sponsored by Transmedics® (Andover, MA, USA). F Rega receives research grants from Medtronic and is a consultant to Atricure Europe (Amsterdam, the Netherlands) and LivaNova Belgium (Zaventem, Belgium). The other authors have no conflicts of interest to declare.